COM:TCR2
Adaptimmune
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.tcr2.comipo date
Feb 14, 2019
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small ...Show More